[ad_1]
Repligen Company (RGEN) Stifel 2025 Healthcare Convention November 11, 2025 10:00 AM EST
Firm Individuals
Olivier Loeillot – President, CEO & Director
Convention Name Individuals
Daniel Arias – Stifel, Nicolaus & Firm, Integrated, Analysis Division
Presentation
Daniel Arias
Stifel, Nicolaus & Firm, Integrated, Analysis Division
I am wrapping up the quarter for lots of those periods. As a kickoff, for Repligen, it was quarter. It was 18% natural development. Every of the important thing product areas was up double digits. Op margins have been 14.2%, down 70 bps and then you definately beat the streak by $0.05 on the underside line.
Query-and-Reply Session
Daniel Arias
Stifel, Nicolaus & Firm, Integrated, Analysis Division
Possibly simply discuss just a little bit about what obtained you there and what you concentrate on the place the assorted parts of the enterprise are proper now?
Olivier Loeillot
President, CEO & Director
Sure. No, completely, Daniel. You are proper. We’re clearly very comfortable about our quarter 3 outcomes. I imply, year-to-date non-COVID natural development of 16%. So clearly, we’re delighted about that. And what I feel is absolutely essential is to determining we actually have that broad and modern portfolio of merchandise. Typically folks tend to summarize our enterprise in a single single product line, however we’re very various. And quarter 3 was a showcase right here the place actually the two franchises that over delivered have been analytics and protein and which was not utterly anticipated to be very open right here, however that was actually shock. And once more, the breadth of our portfolio is an affidavit of how we will develop sooner than market. We have at all times mentioned we need to develop greater than 5% above market development. And this 12 months, we’re in all probability going to be considerably above that.
After which when it comes to market
[ad_2]
